YM Biosciences to acquire Eximias
YM BioSciences, a Canadian cancer product development company, says that it has entered into a definitive agreement to acquire Eximias Pharmaceutical Corp, a privately-held US pharmaceutical firm engaged in the acquisition, development and commercialization of products for the treatment of cancer and cancer-related disorders. On completion of the transaction, Eximias will become a wholly-owned subsidiary of YM, operating as YM BioSciences USA Inc, and will serve as the Canadian group's base of operations in the USA. Eximias currently employs a seasoned management team and has cash resources in excess of $30.0 million.
The merger consideration will consist of part-cash and part-common shares of YM, with at least $25.0 million of the merger consideration consisting of YM common shares. The deal has been clearaed by the boards of directors of both companies and by the stockholders of Eximias. YM shareholders' approval is not required.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze